Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25115763 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ratchanee Duangrat und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand. Hauptthemen laut MEDLINE: Signal Transduction, Receptor, Adenosine A3, Heart Diseases. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 96 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council of Thailand, Mahidol University, Faculty of Pharmacy, Chiang Mai University.
Abstract (Originalsprache)
Cardiovascular diseases (CVDs), particularly heart failure, are major contributors to early mortality globally. Heart failure poses a significant public health problem, with persistently poor long-term outcomes and an overall unsatisfactory prognosis for patients. Conventionally, treatments for heart failure have focused on lowering blood pressure; however, the development of more potent therapies targeting hemodynamic parameters presents challenges, including tolerability and safety risks, which could potentially restrict their clinical effectiveness. Adenosine has emerged as a key mediator in CVDs, acting as a retaliatory metabolite produced during cellular stress via ATP metabolism, and works as a signaling molecule regulating various physiological processes. Adenosine functions by interacting with different adenosine receptor (AR) subtypes expressed in cardiac cells, including A1AR, A2AAR, A2BAR, and A3AR. In addition to A1AR, A3AR has a multifaceted role in the cardiovascular system, since its activation contributes to reducing the damage to the heart in various pathological states, particularly ischemic heart disease, heart failure, and hypertension, although its role is not as well documented compared to other AR subtypes. Research on A3AR signaling has focused on identifying the intricate molecular mechanisms involved in CVDs through various pathways, including Gi or Gq protein-dependent signaling, ATP-sensitive potassium channels, MAPKs, and G protein-independent signaling. Several A3AR-specific agonists, such as piclidenoson and namodenoson, exert cardioprotective impacts during ischemia in the diverse animal models of heart disease. Thus, modulating A3ARs serves as a potential therapeutic approach, fueling considerable interest in developing compounds that target A3ARs as potential treatments for heart diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand.
- Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand.
- Department of Pharmaceutical Sciences, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
- Department of Pharmaceutical Care, Faculty of Pharmacy, Chiang Mai University, Chiang Mai 50200, Thailand.
ORCID-Profile: Ratchanee Duangrat, Warisara Parichatikanond, Supachoke Mangmool
Förderung
- National Research Council of Thailand
- Mahidol University
- Faculty of Pharmacy, Chiang Mai University
Zitieren
APA
Duangrat, R., Parichatikanond, W., Chanmahasathien, W., & Mangmool, S. (2024). Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25115763
Vancouver
Duangrat R, Parichatikanond W, Chanmahasathien W, Mangmool S. Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25115763
BibTeX
@article{Duangrat2024,
author = {Duangrat, Ratchanee and Parichatikanond, Warisara and Chanmahasathien, Wisinee and Mangmool, Supachoke},
title = {Adenosine A3 Receptor: From Molecular Signaling to Therapeutic Strategies for Heart Diseases},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25115763}
}
EUVIMED